Promyelocytic Leukemia Protein (PML) Functions as a Glucocorticoid Receptor Co-activator by Sequestering Daxx to the PML Oncogenic Domains (PODs) to Enhance Its Transactivation Potential*

Ding-Yen LinDagger §, Ming-Zong Lai, David K. Ann||, and Hsiu-Ming ShihDagger §**

From the Dagger  Graduate Institute of Life Sciences, National Defense Medical Center, the § Division of Molecular and Genomic Medicine, National Health Research Institutes, Taipei 11529 Taiwan, Republic of China, the  Institute of Molecular Biology, Academia Sinica, Taipei 11529, Taiwan, Republic of China, and the || Department of Molecular Pharmacology and Toxicology, University of Southern California, Los Angeles, California 90033

Received for publication, January 14, 2003

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Daxx has been reported to function as a transcriptional modulator in the nucleus. In the present study, we have explored the role of Daxx in regulating the transcriptional activity of the glucocorticoid receptor (GR). Overexpression of Daxx suppressed GR-mediated activation of the mouse mammary tumor virus promoter in COS-1, HeLa, and 293T cells. In vitro and in vivo studies revealed that Daxx could directly bind to GR. The mapping analysis further demonstrated that the C-terminal region of Daxx-(501-740) mediates the interaction and transcriptional repression of GR. The repressive effect of Daxx and Daxx-(501-740) on GR could be alleviated by co-expression of promyelocytic leukemia protein (PML). Furthermore, immunofluorescence analysis showed that overexpression of wild-type PML results in the translocation of Daxx and Daxx-(501-740) to the PML oncogenic domains (PODs). By contrast, a PML sumoylation-defective mutant failed to recruit Daxx to PODs and to reverse the Daxx repression effect on GR. Accordingly, As2O3 treatment rendered the sequestration of endogenous Daxx to the PODs, leading to an enhancement of GR transactivation in COS-1 cells. Taken together, these findings suggest that recruitment of Daxx into the subnuclear POD structures sequesters it from the GR/co-activators complex, thereby alleviating its repressive effects. Our present studies provide the important link between Daxx/PML interaction and GR transcriptional activation.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The glucocorticoid receptor (GR),1 a member of the ligand-dependent nuclear receptor superfamily, plays important roles in governing development, growth, apoptosis, and anti-inflammatory processes (1-5). Like other superfamily members, GR contains the N-terminal transactivation domain, central DNA binding domain, and the C-terminal ligand binding domain (6). Prior to exposure to its respective ligand, the GR and other receptors in this family form complexes with heat shock proteins (HSPs), restricting the unliganded-receptor in its inactive state. Upon ligand binding, the receptor is dissociated from HSPs and translocates to the nucleus where the liganded receptor binds to the glucocorticoid-responsive element and recruits co-factors to regulate transcription (7). A diverse group of proteins have emerged as potential cofactors for nuclear receptors through direct protein-protein interactions. For instances, several co-activators have been identified that bind to GR and modulate GR transcriptional activity, including CBP/p300, p160 family co-activators (SRC-1, GRIP1, and p/CIP), and chromatin remodeling complexes (BRG-1 (SWI/SNF) complex and P/CAF (ADA/SAGA) complex) (8, 9). These co-activators appear to be assembled in a multiprotein complex, facilitating the access of nuclear receptors and the RNA polymerase II core machinery to their target DNA by a chromatin remodeling process (10).

In addition to regulating GR transcriptional activity via direct protein-protein interactions, some co-factors appear to modulate GR activity through indirect fashion. PML, a protein located at the promyelocytic oncogenic domains (PODs), has previously been reported to stimulate GR and RXRalpha transcriptional activity through its interaction with CBP (11). These results demonstrated that a portion of CBP is recruited to the PODs through its association with PML, suggesting that PML and/or POD-associated proteins may function as an important cofactor in governing nuclear hormone receptor transcriptional activity and function. Besides PML and CBP, several cellular proteins have been reported to be associated with PODs, including Sp100, Daxx, p53, Rb, small ubiquitin-like modifier (SUMO-1), and BLM (12, 13). Results from many elegant studies have revealed that overexpression of p53 suppressed GR-mediated reporter gene activation (14, 15) and Rb potentiated GR transcriptional activity through its interaction with hBRM (16), respectively. Recently, SUMO-1 modification of GR has been shown to regulate its transcriptional activity (17, 18). These findings suggest that POD-associated proteins play important roles in modulating GR transcriptional activity. Whether other POD-associated proteins are also involved in regulating GR transcriptional activity remains to be explored.

Daxx, a PODs-associated protein, was identified as an interacting protein of PML (19-21). Recent studies implied that Daxx might function as a transcriptional coregulator. Daxx has been shown to exhibit transcriptional repression activity by inhibiting the transcription factor Pax3 and ETS1 through direct protein-protein interactions (22, 23). Most recently, Emelyanov et al. reported that Daxx acts as a transcriptional co-activator or co-repressor of Pax5 in different cellular contexts (24). Although the exact mechanism accounting for these observations is still unclear, the recruitment of nuclear factors possessing either histone acetyltransferase or histone deacetylase activity by Daxx to modulate Pax5 transcriptional activity was proposed (24). In addition, the transcriptional repression effect of Daxx could be modulated by subnuclear compartmentalization through protein-protein interactions. We have recently demonstrated that overexpression of a nucleolar protein MSP58 alleviates the transcriptional repression elicited by Daxx, correlating well with sequestration of Daxx to the nucleolus via Daxx/MSP58 protein-protein interactions (25). Furthermore, Lehembre et al. has shown that SUMO-1-modified PML could relieve the transrepression effect of Daxx on Pax3 transcriptional activity through sequestering Daxx into the PODs (26). Taken together, PML may exert its regulatory effect on transcription factor(s) through altering the compartmentalization of Daxx or other co-regulator(s). This notion led us to raise a question as to whether GR is also regulated by PML, at least in part, through Daxx sequestration to the PODs.

In the present study, we have characterized both biochemical and functional interactions between Daxx and GR. Furthermore, the Daxx-mediated GR repression could be alleviated by the co-expression of wild-type PML but not by a sumoylation-defective PML mutant, which also fails to recruit Daxx to the PODs. Our findings thus provide the first evidence that Daxx could modulate the transcriptional activity of nuclear hormone receptor through protein-protein interactions and sheds light on the mechanism underlying the PML role in modulating nuclear hormone receptor function.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Plasmids Construction-- LexA-Daxx, its deletion mutants LexA-MST3, LexA-lamin, HA-Daxx, and its derived mutant constructs have been described before (25). A mammalian GST-Daxx expression vector was generated by insertion of Daxx into pDEST 26 (Invitrogen). MMTV-Luc and pCMX-PML were kind gifts from Drs. Chawnshang Chang and Ronald Evan, respectively. pGal-AD-GR was engineered by inserting GR coding region into the BamHI and XhoI sites of yeast vector pACT2, which expresses the Gal4 activation domain (Clontech). pCMX-PML-Delta SUMO containing a lysine-to-arginine mutation at amino acid positions 65, 160, and 490 was created in three rounds consecutively of site-directed mutagenesis on the same template pCMX-PML. Site-directed mutagenesis was conducted by using QuikChange site-directed mutagenesis kit according to the manufacturer's instruction (Stratagene).

Two-hybrid Assay and beta -Galactosidase Assay-- Yeast two-hybrid assays were performed as described (25). Briefly, L40 yeast strain was first transformed with individual bait and followed by the prey construct transformation. Yeast transformants were selected on medium lacking histidine, leucine, and tryptophan for four days. His+ colonies were further tested for beta -galactosidase activity. Quantitative X-gal assays were performed with yeasts containing pairs of bait and prey plasmids as indicated. The X-gal activities were determined from three separate liquid yeast cultures according to the instructions of the Galacto-light Plus kit (Tropix Inc., Bedford, MA).

Cell Culture and Transient Transfection-- All mammalian cell lines were obtained from the American Type Culture Collection (ATCC). COS-1, HeLa, and 293T cells were maintained in Dulbecco's minimal essential medium supplemented with 10% fetal bovine serum (FBS) and antibiotics. Cells were seeded into 10-cm plates the day before transfection. Transient transfections were carried out using a LipofectAMINE transfection kit (Invitrogen). Thirty-six hours after the transfection, cells were harvested for co-immunoprecipitation assays and Western blot analyses. For the reporter assays, 2-3 × 105 cells were seeded on 6-well plates for transfection. Four hours prior to transfection, cells received fresh medium with 10% dextran-coated charcoal-stripped FBS. A total of 2 µg of DNA were transfected, including beta -galactosidase expression construct as an indicator for normalization of transfection efficiency. Following transfection, cells were cultured in the medium containing charcoal-stripped 0.05%(V/V) FBS with or without ~10-100 nM dexamethasone and/or further treatment of 1 µM As2O3. Cell lysates were harvested 16 h later and assayed for relative activity (firefly luciferase for the reporter and beta -galactosidase activity for the indicator) as the manufacture instructed (PerkinElmer Life Sciences).

GST Pull-down Assay-- For purification of GST and GST-Daxx fusion proteins, 293T cells were transfected with pDEST26 (Invitrogen) or pDEST26-Daxx. Cells were lysed 48 h later in buffer EM2 containing 50 nM HEPES (pH 7.6), 50 mM NaCl, 1% Nonidet P-40, 5 mM EDTA, 10% glycerol, and 4-(2-aminoethyl)-benzenesulfonyl fluoride (Sigma) and centrifuged at 17,000 × g for 10 min at 4 °C. Supernatants were incubated with glutathione-agarose beads for 1 h at 4 °C. The bound proteins were then analyzed by SDS-PAGE followed by Western blotting using antibody against GST protein. 35S-labeled GR protein was made with the TNT reticulocyte lysate system (Promega). 35S-labeled proteins were incubated with GST or GST-Daxx-agarose beads, which contained equal amounts of protein in 0.2 ml of binding buffer (10 mM HEPES, pH 7.5, 50 mM NaCl, 0.1% Nonidet P-40, 0.5 mM dithiothreitol, and 0.5 mM EDTA) for 2 h, washed four times, and analyzed by SDS-PAGE and autoradiography.

Immunoprecipitation and Western Blotting Assays-- To test the interaction in mammalian cells, wild-type GR along with HA-tagged Daxx expression construct was transfected into COS-1 cells by the lipofection method. Thirty-six hours after cotransfection, cells were solubilized in 1 ml of modified RIPA buffer (50 mM Tris-HCl, pH 7.8, 150 mM NaCl, 5 mM EDTA, 0.5% Triton X-100, 0.5% Nonidet-P40, 0.1% sodium deoxycholate, and protease inhibitor mixture (Complete, Roche Molecular Biochemicals). Cell lysates were mixed with antiserum against HA (Babco, Richmond, CA), Daxx (Santa Cruz Biotechnology, Santa Cruz, CA, catalogue number sc-7152), or GR (Santa Cruz Biotechnology, catalogue number sc-1004), and the immunocomplexes were collected on protein A-Sepharose beads (Amersham Biosciences). Immunoblot analyses of precipitated proteins were performed as described previously (25). The anti-PML antibody was purchased from Santa Cruz Biotechnology (catalogue number sc-966).

Immunofluorescence-- COS-1 cells were plated onto collagen-coated (10 µM) coverslips the day before transfection. The expression vectors of HA-tagged Daxx or its deletion mutants or GR along with PML or PML sumoylation-defective mutant were transiently transfected into COS-1 cells. Twenty-four hours after transfection, the cells received fresh 0.05% stripped FBS and were cultured for an additional 12 h in the presence or absence of 100 nM Dex or 1 µM As2O3 as indicated. Cells were fixed in 4% paraformaldehyde in phosphate-buffered saline and permeabilized with 0.4% Triton X-100. The permeabilized cells were then incubated with an anti-HA monoclonal antibody and an anti-GR polyclonal antibody (Santa Cruz Biotechnology, catalog number sc-1004) for 1 h at room temperature. Following this incubation, cells were washed three times for 10 min with phosphate-buffered saline at room temperature and then incubated at 8 µg/ml with fluorescein isothiocyanate and Texas Red-conjugated anti-rabbit IgG (DAKO) for 1 h at 20 °C. Nuclei were revealed by DAPI staining (10 µg/ml). The coverslips were inverted, mounted on slides, and sealed with nail polish. Pictures were taken using a fluorescent microscopy.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Overexpression of Daxx Suppresses GR-mediated Transactivation of the MMTV Promoter-- To test whether Daxx is involved in regulating GR transcriptional activation, the Daxx expression construct was cotransfected into COS-1 cells along with the GR expression construct and the MMTV-Luc reporter. As shown in Fig. 1A, Daxx suppressed GR-mediated transactivation in a dose-dependent fashion. By contrast, a transcriptional co-activator, GRIP1, potentiated the transactivation ability of GR. Furthermore, the repressive effect of Daxx on GR was also observed in other cell lines, such as HeLa and 293T cells (Fig. 1B), indicating that the Daxx-dependent GR repression is not a cell type-specific event.


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 1.   Repression of glucocorticoid-stimulated MMTV-LTR-driven luciferase activity by Daxx. A, COS-1 cells were transiently transfected in 6-well plates with 500 ng of pMMTV-Luc, 50 ng of pSV40-beta -galactosidase, 500 ng of pKSR-GR, and increasing amounts of HA-Daxx plasmids as indicated or 500 ng of pCMV-GRIP1. The total amount of plasmid transfected per well were kept constant by addition of empty pcDNA3 vector as needed. Transfected cells were incubated in complete medium for 16-18 h, then washed, and incubated in Dulbecco's modified Eagle's medium with 0.05% charcoal-stripped fetal calf serum with or without 100 nM dexamethasone (Dex) for another 24 h. Relative luciferase activity is represented as mean ± S.D. (luciferase light units/beta -galactosidase). B, the effect of Daxx on GR-mediated transcription of pMMTV-Luc reporter was assayed in COS-1, HeLa, and 293T cells. Five hundred nanograms of luciferase reporters, 50 ng of pSV40-beta -galactosidase, 500 ng of pKSR-GR, and 500 ng of HA-Daxx plasmids per well were used in these experiments.

Daxx Binds to GR Both in Vitro and in Vivo-- To explore whether the transcriptional repression of GR by Daxx is through the direct protein-protein interaction between Daxx and GR, we first performed the co-immunoprecipitation experiments. COS-1 cells were cotransfected with expression constructs encoding GR and HA-Daxx and followed by treatment of dexamethasone. Forty-eight hours after transfection, cell lysates were subjected to immunoprecipitation assays with an anti-GR antibody followed by Western blot analyses with an anti-HA antibody. As shown in Fig. 2A, Daxx was detected in the immunoprecipitated complexes of GR (top panel, lane 4). This interaction was also validated in a reciprocal co-immunoprecipitation assay (data not shown). These results suggest that Daxx and GR can associate to form complexes in mammalian cells.


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 2.   Interaction between GR and Daxx in vitro and in vivo. A, GR interacts with Daxx in transfected COS-1 cells. COS-1 cells were transiently transfected with the indicated combinations of expression constructs encoding GR and HA-tagged Daxx, respectively. Following treatment with 100 nM Dex for 30 h, total cell lysates were analyzed by Western blot (WB) to check expression of GR and Daxx proteins (bottom panel). Equal amounts of cell lysates were immunoprecipitated (IP) with an anti-GR antibody, followed by blotting with an anti-HA antibody (upper panel), whereas reciprocal co-immunoprecipitation experiments were performed using an anti-HA antibody, followed by blotting with an anti-GR antibody (data not shown). B, interaction of GST-Daxx with in vitro translated GR. The GST or GST-Daxx fusion proteins were immobilized on the glutathione-agarose beads and then incubated with in vitro translated [35S]methionine-labeled GR protein. After wash, the bound components were resolved on a 10% SDS-polyacrylamide gel. The 20% amount of input GR was shown as a positive control for GR. Immunoblotting analysis of GST and GST-Daxx protein using an antibody against GST were aligned to show protein levels (bottom panel).

To further test whether this association is through direct protein-protein interaction, GST pull-down assays were performed using GST-Daxx fusion protein and in vitro translated [35S]methionine-labeled GR. As shown in Fig. 2B, GR was specifically pulled down by GST-Daxx but not by GST protein, indicating that GR binds to Daxx directly. It should be noted that the interaction between GR and Daxx was not affected by the presence or absence of dexamethasone. To further substantiate the observed direct protein-protein interaction between Daxx and GR, we also carried out the yeast two-hybrid assays. The GR cDNA clone was subcloned in frame into pACT2 vector (Gal AD-GR) and subsequently analyzed with different bait proteins (Daxx, MST3, and lamin) for the ability to activate His3 and LacZ reporter genes. As summarized in Fig. 3B, yeast co-transformed with GalAD-GR and LexA-Daxx was able to form colonies in the medium plate lacking histidine, indicating a positive interaction between GR and Daxx. Again, this interaction is specific since no interaction between GR and lamin or MST3 was detected. The interaction was further verified by liquid beta -galactosidase assay (Fig. 3C). Taken together, our results clearly demonstrated that GR interacts with Daxx through direct protein-protein interactions.


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 3.   The COOH domain of Daxx mediates the interaction and transcriptional repression of GR. A, schematic presentation of different Daxx deletion mutants tested in yeast two-hybrid and mammalian transfection assays. The LexA constructs of Daxx(FL), Daxx-(1-625), Daxx-(1-501), and Daxx-(501-740) used in yeast two-hybrid assays represent the fusion proteins between LexA and various Daxx deletion mutants. All Daxx deletion mutants were also fused to a HA tag for the purpose of detection in the mammalian cells. Proteins reported to interact with different regions of Daxx are indicated. B, domain mapping studies of Daxx associated with GR. The wild-type and the deletion mutants of Daxx as indicated (amino acid residue in parentheses) were fused to the LexA DNA binding domain. The LexA-lamin and LexA-MST3 serve as negative controls. GR fused to Gal4 activation domain functions as prey for interaction. Yeast transformants were streaked on histidine-auxotroph selection plates and scored after a 4-day incubation at 30 °C. Growth is indicated as "-" to "++++" based on the size of the colonies. C, liquid X-gal assay for Daxx-GR interactions. The relative strength of protein interactions was determined by measuring beta -galactosidase activities using the Galacto-light Plus kit (Tropix Inc.) and normalized by cell density (A600). The bar graph shows the average activity observed from two independent experiments performed in triplicate. D, the effect of Daxx mutants on glucocorticoid-stimulated MMTV-LTR-driven luciferase activity in COS-1 cells. Transient transfection was conducted as described in Fig. 1A. COS-1 cells were cotransfected with MMTV-Luc reporter, the expression vector for GR, together with expression plasmids for either of the different Daxx mutants. Data presented here are the means of at least three independent experiments. E, Western blot showing the expression of different Daxx mutant whole cell extracts were analyzed on a 10% SDS-polyacrylamide gel transferred to Immobilon-P membrane and probed by the anti-HA antibody. Numbers indicate size markers.

The Functional Interaction between the C-terminal Domain of Daxx and GR-- To delineate the region(s) of Daxx that is involved in Daxx/GR interaction, various deletion constructs of Daxx were engineered (Fig. 3A) and subjected to analyses in yeast two-hybrid assays. The strength of interaction was scored by the colony growth in histidine-auxotroph-selective medium and quantified by liquid beta -galactosidase assay. As shown in Fig. 3B, the C terminus-deleted Daxx (amino acids 1-501 and 1-625) failed to interact with GR. In contrast, the mutant with a deletion of amino acid residues 1-501 of Daxx was still capable of interacting with GR, albeit the strength of interaction with GR was less than that from the full-length Daxx. Additionally, consistent results were also observed with the liquid beta -galactosidase assay. Altogether, these results implicated that the C-terminal region of Daxx is necessary and sufficient for its interaction with GR.

To establish the correlation between interaction and GR transcriptional repression by Daxx, these Daxx mutants were analyzed for their respective abilities to repress GR transactivation. As illustrated in Fig. 3D, overexpression of Daxx-(501-740), like full-length Daxx, was capable of suppressing GR-mediated transcriptional activation, whereas both Daxx-(1-501) and Daxx-(1-625) failed to do so, indicating that the C-terminal region of Daxx is sufficient for Daxx-mediated GR transrepression. Taken together, these findings provide direct evidence that the interaction between Daxx and GR correlates well with Daxx function as a GR transrepressor.

PML Reverses Daxx Transrepression of GR by Recruiting Daxx to the PODs-- Recent studies indicated that PML overexpression reverses the Daxx-dependent transcriptional repression and such a de-repression correlates well with the ability of sumoylated PML to sequester Daxx to the PODs (21). In this scenario, we anticipated that PML should be able to relieve the Daxx transrepression on GR activity. To test this possibility, COS-1 cells were cotransfected with PML expression construct along with the expression constructs harboring either full-length Daxx or Daxx-(501-740) and assayed for GR transactivation potential. As shown in Fig. 4A, overexpression of PML resulted in a reduction of transrepression elicited by both Daxx and Daxx-(501-740) on GR in a dose-dependent manner. To further unveil whether this de-repression by PML correlates with the recruitment of Daxx to the PODs, immunofluorescent analyses were performed. COS-1 cells were transiently transfected with a combination of GR, PML, HA-Daxx, HA-Daxx-(1-625), and HA-Daxx-(501-740) as indicated and then subsequently stained with the appropriate antibodies, followed by immunofluorescence analysis. When HA-Daxx or HA-Daxx-(501-740) was overexpressed alone, a fairly diffuse and evenly distributed staining pattern was observed through the nucleus (Fig. 4B, a and i). By contrast, HA-Daxx-(1-625) gave an exclusively cytoplasmic staining pattern (e), suggesting that the C-terminal region of Daxx-(626-740) is required for the nuclear localization. Notably, co-expression of PML resulted in a dramatic change of HA-Daxx and HA-Daxx-(501-740) distribution patterns (b and j), as evidenced by the Daxx-PML colocalized to the PODs (d and l). Conversely, the cytoplasmic distribution of HA-Daxx-(1-625) was not altered by PML, supporting the previous findings that PML fails to interact with Daxx-(1-625) (h). Taken together, these findings evidently suggest that the de-repression by PML is through its ability to sequester Daxx to PODs. It is very worthy of knowing that the distribution of GR was not altered upon PML overexpression (Fig. 4B, m), consistent with the notion that PML did not directly bind to GR (11).2


View larger version (38K):
[in this window]
[in a new window]
 
Fig. 4.   PML activates GR transactivation through sequestration of Daxx. A, PML relieves the Daxx transrepression effect on GR transcriptional activity. COS-1 cells were transfected in six-well plates with MMTV-Luc, beta -galactosidase, GR, Daxx(FL), or Daxx-(501-740), and indicated amounts of PML expression plasmids. Transfected cells were incubated in complete medium for 16-18 h and then grown in the absence or presence of 10 nM Dex for another 24 h. Luciferase activity was reported as relative light units and represented as the mean ± S.D. B, PML overexpression induces the recruitment of Daxx but not that of GR to the PODs. COS-1 cells were transiently transfected with plasmid constructs as indicated. The cells transfected with GR and PML were treated with 100 nM Dex for 3 h before fixation. The primary antibodies used in immunostaining analyses were the PG-M3 monoclonal antibody against PML, the rabbit polyclonal anti-GR antibody (M-20) against GR, and a rabbit polyclonal anti-HA antibody (Y-11) against the HA-tagged Daxx and its derivative proteins. The secondary antibodies for these studies were fluorescein isothiocyanate-conjugated anti-mouse immunoglobulin G and Texas Red-conjugated anti-rabbit immunoglobulin G. After immunostaining and washing procedures, the samples were analyzed by immunofluorescence microscopy. 4',6'-Diamidino-2-phenylindole (DAPI) staining revealed the positions of the nucleus. Immunofluorescence micrographs of immunolabeled proteins are presented with the respective colors in the lower corners of the image. Superimposing the two colors (Merged) results in a yellow signal.

To further substantiate that the recruitment of Daxx by PML to PODs plays an important role in regulating GR transcriptional activity, a PML sumoylation-defective mutant was subjected to the same analyses for its ability to recruit Daxx to the PODs and to reverse the transrepression elicited by Daxx on GR. Notably, co-expression of sumoylation-defective PML mutant failed to recruit Daxx from nucleoplasm to PODs (Fig. 5A). As expected, sumoylation-defective PML mutant, unlike the wild-type PML, was unable to relieve the Daxx transrepression effect on GR (Fig. 5B), indicating that the Daxx-mediated GR transrepression and the recruitment of Daxx to PODs by PML are an interdependent event. To further demonstrate the effect exerted by PML on the Daxx-dependent GR transrepression and the Daxx nuclear compartmentalization, we treated COS-1 cells with As2O3. As2O3 has been shown to promote the SUMO-1 modification of PML, which in turn induces the recruitment of PML and Daxx to the PODs (19, 21, 26). As shown in Fig. 6A, As2O3 treatment caused a marked increase of the number of POD formation, as evidenced by immunofluorescent analysis of endogenous PML (a and d). This treatment also rendered the redistribution of endogenous Daxx from nucleoplasm to the PODs, leading to the co-localization of Daxx with PML (b and e). Coordinately, As2O3 treatment resulted in an increment of the GR-mediated transcriptional activity (Fig. 6B). Taken together, the results of transient cotransfection assays and immunofluorescence studies unequivocally indicate that PML potentiates GR transcriptional activation by compartmentalizing Daxx from nucleoplasm to the PODs.


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 5.   Correlation between Daxx compartmentalization and GR transrepression. A, sumoylation-defective PML did not recruit the Daxx into the PODs. Double immunofluorescence staining of Daxx and PML or sumoylation-defective PML was performed on the transfected COS-1 cells. The staining pattern was determined as in Fig. 4A. B, SUMO-1 modification of PML is essential for suppressing Daxx-mediated repression of GR transcriptional activity. PML or sumoylation-defective PML, GR, and Daxx(FL) expression constructs were cotransfected in COS-1 cells as indicated with the MMTV-Luc reporter construct. Expression levels of PML and sumoylation-defective PML were immunoblotted with an anti-PML antibody from the whole cell lysates.


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 6.   As2O3 stimulates the translocation of Daxx to PODs and potentiates the GR-mediated transactivation. A, COS-1 cells were treated with 1 µM As2O3 for 12 h, and then double immunofluorescence staining of endogenous Daxx and PML was performed. The staining pattern was determined as in Fig. 4A. B, COS-1 cells were transfected with the MMTV-Luc reporter and GR expression constructs. Following the transfection, cells were pretreated with 100 nM Dex for 12 h and then incubated in medium with or without 1 µM As2O3 for another 12 h. Luciferase activity was then determined as described above.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In the present studies, we have identified Daxx as a GR-interacting protein and demonstrated that Daxx regulates the GR transcriptional activation on MMTV promoter. We provided biochemical evidence that Daxx associates with GR in yeast, in vitro, and in mammalian cells. The interaction between GR and Daxx is mediated through the C-terminal region of Daxx. Furthermore, co-expression of PML relieves the transcriptional repression by Daxx, correlating well with the recruitment of Daxx from the nucleoplasm to the PODs. Our findings not only provide the first direct link between Daxx expression and GR activity but also shed some light on the molecular mechanism underlying the role of PML in regulating GR transcriptional potential.

Daxx was initially identified as the adaptor molecule between Fas receptor and Jun N-terminal kinase in Fas-mediated apoptosis (27). However, accumulated evidence suggested that Daxx might function as a transcriptional repressor through its interaction with a growing number of transcription factors. Daxx has been shown to repress the basal activity by a heterologous TK promoter through Gal4DBD-Daxx fusion (19, 21, 25). Daxx was also reported to inhibit the activity of the transcriptional activators Pax3 and ETS1 (22, 23). While Daxx overexpression inhibited the endogenous Pax5 transcriptional activity in the human HS-Sultan cell line and the murine plasmacytoma J558L cell line, Daxx potentiated Pax5 transcriptional activity in M12.4.1 and A20 murine B cells (24). In the present study, we further demonstrated that Daxx could suppress the GR-mediated transcriptional activation of MMTV reporter. The transrepressional effect of Daxx on GR activity has also been demonstrated in several cell lines, indicating that this repressive effect is likely not a cell type-specific event. Furthermore, we also provided biochemical and cell biological evidence that the C-terminal region of Daxx is necessary and sufficient to interact with GR and repress GR transcriptional activity. Intriguingly, this C-terminal region of Daxx has also been reported to interact with other transcription factors, such as Pax3, Pax5, and ETS1 (19, 23, 24) as well as a wide variety of molecules, including Fas receptor, PML, centromeric protein CENP-C, DNA methyltransferase I, HSP27, Glut4, Ubc9, and SUMO-1 (21, 27-32). Conceivably, the C-terminal region of Daxx acts as a major docking domain for protein-protein interactions. To our knowledge, it is not yet demonstrated how this domain provides a binding surface for these proteins with such distinctive functions. However, we postulate that Daxx is likely involved in the signaling pathway cross-talks through competitive binding by distinct factors to the specific motif(s) located within the C-terminal domain of Daxx.

Although Daxx functions as a transcriptional co-repressor, the molecular mechanism as to how it suppresses the transcriptional activation remains largely unknown. Previous report showed that the treatment with a deacetylase inhibitor, trichostatin A, efficiently reversed the repressive effect of Daxx (21), suggesting that histone deacetylation may be involved in Daxx-mediated transcriptional repression. Consistently, interaction between the Daxx and HDAC1 has been demonstrated by in vitro pull-down assay and in vivo overexpression experiments (21). Furthermore, Hollenbach et al. has recently shown that endogenous hDaxx eluted from size exclusion chromatography column has an apparent molecular mass of 360 kDa and associates with multiple proteins that are critical for transcriptional repression, such as histone deacetylase II, components of chromatin such as core histone H2A, H2B, H3, and H4, and a chromatin-associated protein Dek (33). The findings of the hDaxx association with histone deacetylase are consistent with our notion that HDACs play an essential role in Daxx-mediated transcriptional modulation via chromatin remodeling processes. Moreover, that Daxx was reported to be associated with condensed chromatin in the cells lacking PML (20) also supports the role of Daxx in the establishment and/or maintenance of a transcriptionally silenced chromatin structure. Whether overexpressed Daxx results in silencing the chromatin structure of GR-regulated genes remains to be explored.

Another main feature of the present study is to explore the mechanism as to how PML regulates GR transcriptional activity. PML has been proposed to function as a transcription cofactor through recruiting co-activators (13, 34). For example, PML has been shown to potentiate the transactivation activity of AP-1 and progesterone receptor (35, 36). Further studies revealed that PML does not interact directly with either Jun/Fos or progesterone receptor but instead targets transcriptional co-activators, such as CBP and TIF1alpha (11, 36, 37). PML binds to CBP in vitro, promotes CBP localization to PODs, and enhances transcriptional activity of nuclear receptors such as GR and retinoid-X receptor in transient transfection assays (11). Similarly, a co-activator complex, composed of PML, TIF1alpha , and CBP, is recruited to retinoic acid response element, suggesting that PML is a co-activator for retinoic acid receptors (37). In this study, we propose an alternative regulatory route for PML in modulating GR transactivation function. The recruitment of Daxx to PODs by PML may represent another mechanism whereby the activity of the GR is activated. Our results clearly demonstrated that wild-type but not sumoylation-defective PML is critical for attenuating transrepression effect of Daxx on GR by translocating Daxx to the PODs. Likewise, that As2O3-treatment enhanced GR transcriptional activation utilizes a similar mechanism by modulating Daxx localization. These findings are consistent with the established notion from recent studies that SUMO-1 modification of PML is required for both the sequestration of Daxx to the PODs and efficient inhibition of Daxx-mediated repression. One may hypothesize that retention of Daxx into PODs through PML overexpression would prevent the access of Daxx to GR, subsequently impeding its repressive action. Likewise, Lehembre et al. have recently reported that SUMO-1-modified PML could derepress Pax3 transcriptional activity through sequestration of the Daxx repressor into the PODs (26). Taken together, these findings suggest that PML may modulate the activities of a variety of transcription factors by altering the compartmentalization of its respective co-repressor(s) to the PODs. Comparable to this scenario, we have recently identified that nucleolar protein MSP58 can enhance the transactivation potential by sequestering Daxx to the nucleolus (25). In light of these observations, PODs and/or nucleolus may participate to the transcriptional activation of specific target genes by tethering co-repressors, such as Daxx, from the diffuse nuclear fraction where transcription takes place.

    FOOTNOTES

* This work was supported by intramural funds of National Health Research Institutes (to H.-M. S.) and in part by National Institute of Health Research Grants R01 DE10742 and DE14183 (to D. K. A.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

** To whom correspondence should be addressed: Div. of Molecular and Genomic Medicine, National Health Research Institutes, 128 Sec2, Yen-Chiu-Yuan Rd., Taipei 11529, Taiwan. Tel.: 886-2-2652-4122; Fax: 886-2-27890484; E-mail: shihh@nhri.org.tw.

Published, JBC Papers in Press, February 20, 2003, DOI 10.1074/jbc.M300387200

2 D.-Y. Lin and H.-M. Shih, unpublished data.

    ABBREVIATIONS

The abbreviations used are: GR, glucocorticoid receptor; MSP58, 58-kDa microspherule protein; Dex, dexamethasone; PML, promyelocytic leukemia protein; PODs, PML oncogenic domains; SUMO, small ubiquitin-like modifier; CBP, CREB binding protein; FBS, fetal bovine serum; GST, glutathione S-transferase; X-gal, 5-bromo-4-chloro-3-indolyl-beta -D-galactopyranoside; HA, hemagglutinin; DAPI, 4',6-diamidino-2-phenylindole; MMTV, murine mammary tumor virus.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Barnes, P. J. (1998) Clin. Sci. (Lond) 94, 557-572[Medline] [Order article via Infotrieve]
2. Sapolsky, R. M., Romero, L. M., and Munck, A. U. (2000) Endocr. Rev. 21, 55-89[Abstract/Free Full Text]
3. Adcock, I. M. (2001) Pulm. Pharmacol. Ther. 14, 211-219[CrossRef][Medline] [Order article via Infotrieve]
4. Almawi, W. Y., and Melemedjian, O. K. (2002) J. Leukoc. Biol. 71, 9-15[Abstract/Free Full Text]
5. Distelhorst, C. W. (2002) Cell Death Differ. 9, 6-19[CrossRef][Medline] [Order article via Infotrieve]
6. Olefsky, J. M. (2001) J. Biol. Chem. 276, 36863-36864[Free Full Text]
7. Beato, M., and Sanchez-Pacheco, A. (1996) Endocr. Rev. 17, 587-609[Medline] [Order article via Infotrieve]
8. Robyr, D., Wolffe, A. P., and Wahli, W. (2000) Mol. Endocrinol 14, 329-347[Free Full Text]
9. Rosenfeld, M. G., and Glass, C. K. (2001) J. Biol. Chem. 276, 36865-36868[Free Full Text]
10. Collingwood, T. N., Urnov, F. D., and Wolffe, A. P. (1999) J. Mol. Endocrinol. 23, 255-275[Abstract/Free Full Text]
11. Doucas, V., Tini, M., Egan, D. A., and Evans, R. M. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 2627-2632[Abstract/Free Full Text]
12. Hatta, M., and Fukamizu, A. (2001) Science's STKE, http://stke.sciencemag.org/cgi/content/full/sigtrans;2001/112/e1
13. Borden, K. L. (2002) Mol. Cell. Biol. 22, 5259-5269[Free Full Text]
14. Yu, C., Yap, N., Chen, D., and Cheng, S. (1997) Cancer Lett. 116, 191-196[CrossRef][Medline] [Order article via Infotrieve]
15. Sengupta, S., Vonesch, J. L., Waltzinger, C., Zheng, H., and Wasylyk, B. (2000) EMBO J. 19, 6051-6064[Abstract/Free Full Text]
16. Singh, P., Chan, S. W., and Hong, W. (2001) J. Biol. Chem. 276, 13762-13770[Abstract/Free Full Text]
17. Le Drean, Y., Mincheneau, N., Le Goff, P., and Michel, D. (2002) Endocrinology 143, 3482-3489[Abstract/Free Full Text]
18. Tian, S., Poukka, H., Palvimo, J. J., and Janne, O. A. (2002) Biochem. J. 367, 907-911[CrossRef][Medline] [Order article via Infotrieve]
19. Torii, S., Egan, D. A., Evans, R. A., and Reed, J. C. (1999) EMBO J. 18, 6037-6049[Abstract/Free Full Text]
20. Ishov, A. M., Sotnikov, A. G., Negorev, D., Vladimirova, O. V., Neff, N., Kamitani, T., Yeh, E. T., Strauss, J. F., III, and Maul, G. G. (1999) J. Cell Biol. 147, 221-234[Abstract/Free Full Text]
21. Li, H., Leo, C., Zhu, J., Wu, X., O'Neil, J., Park, E. J., and Chen, J. D. (2000) Mol. Cell. Biol. 20, 1784-1796[Abstract/Free Full Text]
22. Hollenbach, A. D., Sublett, J. E., McPherson, C. J., and Grosveld, G. (1999) EMBO J. 18, 3702-3711[Abstract/Free Full Text]
23. Li, R., Pei, H., Watson, D. K., and Papas, T. S. (2000) Oncogene 19, 745-753[CrossRef][Medline] [Order article via Infotrieve]
24. Emelyanov, A. V., Kovac, C. R., Sepulveda, M. A., and Birshtein, B. K. (2002) J. Biol. Chem. 277, 11156-11164[Abstract/Free Full Text]
25. Lin, D. Y., and Shih, H. M. (2002) J. Biol. Chem. 277, 25446-25456[Abstract/Free Full Text]
26. Lehembre, F., Muller, S., Pandolfi, P. P., and Dejean, A. (2001) Oncogene 20, 1-9[CrossRef][Medline] [Order article via Infotrieve]
27. Yang, X., Khosravi-Far, R., Chang, H. Y., and Baltimore, D. (1997) Cell 89, 1067-1076[Medline] [Order article via Infotrieve]
28. Charette, S. J., and Landry, J. (2000) Ann. N. Y. Acad. Sci. 926, 126-131[Abstract/Free Full Text]
29. Michaelson, J. S., Bader, D., Kuo, F., Kozak, C., and Leder, P. (1999) Genes Dev. 13, 1918-1923[Abstract/Free Full Text]
30. Pluta, A. F., Earnshaw, W. C., and Goldberg, I. G. (1998) J. Cell Sci. 111, 2029-2041[Medline] [Order article via Infotrieve]
31. Lalioti, V. S., Vergarajauregui, S., Pulido, D., and Sandoval, I. V. (2002) J. Biol. Chem. 277, 19783-19791[Abstract/Free Full Text]
32. Ryu, S. W., Chae, S. K., and Kim, E. (2000) Biochem. Biophys. Res. Commun. 279, 6-10[CrossRef][Medline] [Order article via Infotrieve]
33. Hollenbach, A. D., McPherson, C. J., Mientjes, E. J., Iyengar, R., and Grosveld, G. (2002) J. Cell Sci. 115, 3319-3330[Abstract/Free Full Text]
34. Lin, R. J., Sternsdorf, T., Tini, M., and Evans, R. M. (2001) Oncogene 20, 7204-7215[CrossRef][Medline] [Order article via Infotrieve]
35. Guiochon-Mantel, A., Savouret, J. F., Quignon, F., Delabre, K., Milgrom, E., and De The, H. (1995) Mol. Endocrinol 9, 1791-1803[Abstract]
36. Vallian, S., Gaken, J. A., Gingold, E. B., Kouzarides, T., Chang, K. S., and Farzaneh, F. (1998) Oncogene 16, 2843-2853[CrossRef][Medline] [Order article via Infotrieve]
37. Zhong, S., Delva, L., Rachez, C., Cenciarelli, C., Gandini, D., Zhang, H., Kalantry, S., Freedman, L. P., and Pandolfi, P. P. (1999) Nat. Genet. 23, 287-295[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.